ProQR Therapeutics (PRQR) Depreciation & Amortization (CF) (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $789740.3 the latest figure, recorded in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 2.36% year-over-year to $789740.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 1.06% YoY) and the FY2025 annual result came in at $3.1 million, down 2.1% from the prior year.
• Depreciation & Amortization (CF) advanced to $789740.3 in Q1 2026 per PRQR's latest filing, from $772671.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for PRQR reached as high as $851189.8 in Q4 2022 and fell as low as $624736.9 in Q1 2023.
• A 5-year average of $749175.5 and a median of $768119.1 in 2025 frame the typical range for Depreciation & Amortization (CF).
• The largest YoY upside for Depreciation & Amortization (CF) was 35.51% in 2022 against a maximum downside of 9.67% in 2022.
• Year by year, Depreciation & Amortization (CF) stood at $851189.8 in 2022, then slipped by 2.67% to $828430.7 in 2023, then dropped by 7.83% to $763567.3 in 2024, then increased by 1.19% to $772671.0 in 2025, then increased by 2.21% to $789740.3 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $789740.3, $772671.0, and $763567.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.